open access

Vol 13, No 4 (2017)
Review paper
Published online: 2017-09-13
Get Citation

Metronomic chemotherapy in breast cancer

Katarzyna Pogoda, Maciej Krzakowski, Agnieszka Jagiełło-Gruszfeld
DOI: 10.5603/OCP.2017.0018
·
Oncol Clin Pract 2017;13(4):161-168.

open access

Vol 13, No 4 (2017)
REVIEW ARTICLES
Published online: 2017-09-13

Abstract

New effective therapies are under development in breast cancer; at the same time attempts are being made to modify the dosage of already available drugs. The major challenge is to treat patients with multiple comorbidities who are not candidates for standard chemotherapy. An alternative for these patients may be a metronomic chemotherapy, which is based on continuous administration of drugs at very low doses every day or in short intervals. This also cause antiangiogenic and immune-modulating effects. The tolerance of the metronomic therapy is better, which improves the patients’ quality of life. More and more data indicate the use of multidrug metronomic regimens in a broader group of breast cancer patients.

This article discusses the use of metronomic chemotherapy in patients with metastatic breast cancer, highlighting the most well—established regimens, which should be considered first of all in elderly patients with comorbidities, who do not need a rapid response to therapy. Published data support also the consideration of the use of multi-drug metronomic chemotherapy in wider group of breast cancer patients. The course of research in this approach has been outlined in patients undergoing adjuvant therapy and receiving maintenance treatment in patients with triple negative breast cancer.

Abstract

New effective therapies are under development in breast cancer; at the same time attempts are being made to modify the dosage of already available drugs. The major challenge is to treat patients with multiple comorbidities who are not candidates for standard chemotherapy. An alternative for these patients may be a metronomic chemotherapy, which is based on continuous administration of drugs at very low doses every day or in short intervals. This also cause antiangiogenic and immune-modulating effects. The tolerance of the metronomic therapy is better, which improves the patients’ quality of life. More and more data indicate the use of multidrug metronomic regimens in a broader group of breast cancer patients.

This article discusses the use of metronomic chemotherapy in patients with metastatic breast cancer, highlighting the most well—established regimens, which should be considered first of all in elderly patients with comorbidities, who do not need a rapid response to therapy. Published data support also the consideration of the use of multi-drug metronomic chemotherapy in wider group of breast cancer patients. The course of research in this approach has been outlined in patients undergoing adjuvant therapy and receiving maintenance treatment in patients with triple negative breast cancer.

Get Citation

Keywords

metronomic chemotherapy, advanced breast cancer, maintenance therapy, toxicity, quality of life

About this article
Title

Metronomic chemotherapy in breast cancer

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 4 (2017)

Article type

Review paper

Pages

161-168

Published online

2017-09-13

DOI

10.5603/OCP.2017.0018

Bibliographic record

Oncol Clin Pract 2017;13(4):161-168.

Keywords

metronomic chemotherapy
advanced breast cancer
maintenance therapy
toxicity
quality of life

Authors

Katarzyna Pogoda
Maciej Krzakowski
Agnieszka Jagiełło-Gruszfeld

References (36)
  1. Cardoso F, Colleoni M, Leo ADi, et al. Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. Cancer Treatment Communications. 2016; 6: S1–S10.
  2. André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014; 11(7): 413–431.
  3. Munzone E, Colleoni M. Clinical overview of metronomic chemotherapy in breast cancer. Nat Rev Clin Oncol. 2015; 12(11): 631–644.
  4. Cardoso F, Costa A, Senkus E, et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology. 2016: mdw544.
  5. Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011; 29(34): 4498–4504.
  6. Martín M, Martínez N, Ramos M, et al. Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. Oncologist. 2015; 20(2): 111–112.
  7. Rajdev L, Negassa A, Dai Q, et al. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol. 2011; 68(5): 1119–1124.
  8. Addeo R, Sgambato A, Cennamo G, et al. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer. 2010; 10(4): 301–306.
  9. De Iuliis F, Salerno G, Taglieri L, et al. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori. 2015; 101(1): 30–35.
  10. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002; 13(1): 73–80.
  11. Cazzaniga ME, Torri V, Villa F, et al. Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study. Int J Breast Cancer. 2014; 2014: 769790.
  12. Cazzaniga ME, Cortesi L, Ferzi A, et al. VICTOR Study Group. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat. 2016; 160(3): 501–509.
  13. Brems-Eskildsen AS, Linnet S, Luczak A i wsp. Metronomic chemotherapy is better tolerated and as effective as standard chemotherapy. Results from the XeNa trial; a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. Poster presentation at 10th European Breast Cancer Conference. Amsterdam, The Netherlands, 09-11 March 2016.
  14. Yoshimoto M, Takao S, Hirata M, et al. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2012; 70(2): 331–338.
  15. Montagna E, Lai A, Palazzo A, et al. 1876 A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination. Eur J Cancer. 2015; 51: S291–S292.
  16. Rochlitz C, Moos R, Biger M, et al. SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer — A multicenter, randomized phase III trial. J Clin Oncol. 2014; 21((suppl.)): Abstract 518.
  17. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006; 6: 225.
  18. Aurilio G, Munzone E, Botteri E, et al. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. Breast J. 2012; 18(5): 470–474.
  19. Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol. 2006; 17(2): 232–238.
  20. Mayer EL, Isakoff SJ, Klement G, et al. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012; 136(1): 169–178.
  21. Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014; 32(32): 3626–3633.
  22. Montagna E, Cancello G, Bagnardi V, et al. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer. 2012; 12(3): 207–214.
  23. Liu Y, Gu F, Liang J, et al. The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis. PLoS One. 2017; 12(3): e0173693.
  24. Biganzoli L, Lichtman S, Michel JP, et al. Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer. 2015; 51(17): 2491–2500.
  25. Coates AS, Winer EP, Goldhirsch A, et al. Panel Members. Tailoring therapies — improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8): 1533–1546.
  26. Senkus E, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v8–30.
  27. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006; 24(22): 3623–3628.
  28. Dellapasqua S, Mazza M, Rosa D, et al. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast. 2011; 20(4): 319–323.
  29. Ellis GK, Barlow WE, Gralow JR, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011; 29(8): 1014–1021.
  30. Cancello G, Bagnardi V, Sangalli C, et al. Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. Clin Breast Cancer. 2015; 15(4): 259–265.
  31. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990; 8(9): 1483–1496.
  32. Crivellari D, Gray KP, Dellapasqua S, et al. International Breast Cancer Study Group. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast. 2013; 22(2): 130–137.
  33. Alagizy HA, Shehata MA, Hashem TA, et al. Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer. Hematol Oncol Stem Cell Ther. 2015; 8(1): 22–27.
  34. Shawky H, Galal S. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy--a single-arm phase II study. J Egypt Natl Canc Inst. 2014; 26(4): 195–202.
  35. Nasr KE, Osman MA, Elkady MS, et al. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Ann Transl Med. 2015; 3(19): 284.
  36. Colleoni M, Gray KP, Gelber S, et al. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol. 2016; 34(28): 3400–3408.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl